InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
twodogsbr549 Free
01/23/20 10:05 AM
profile icon
georgie18 PremiumMember
01/15/20 10:25 AM
profile icon
RodinLP Free
01/15/20 1:23 AM
profile icon
knoxlube Free
01/14/20 3:50 PM
profile icon
RodinLP Free
01/14/20 3:13 PM
profile icon
knoxlube Free
01/14/20 11:32 AM
profile icon
eom7 Free
01/14/20 11:29 AM
profile icon
knoxlube Free
01/14/20 11:23 AM
profile icon
twodogsbr549 Free
01/14/20 11:09 AM
profile icon
knoxlube Free
01/14/20 10:54 AM
profile icon
knoxlube Free
01/14/20 10:43 AM
profile icon
knoxlube Free
01/14/20 10:12 AM
profile icon
eom7 Free
01/14/20 10:11 AM
profile icon
eom7 Free
01/14/20 9:45 AM
profile icon
twodogsbr549 Free
01/13/20 8:49 PM
profile icon
RodinLP Free
01/11/20 3:19 AM
profile icon
RodinLP Free
01/10/20 3:36 PM
profile icon
RodinLP Free
01/10/20 1:38 PM
profile icon
RodinLP Free
01/09/20 4:57 PM
profile icon
knoxlube Free
01/09/20 11:08 AM
profile icon
RodinLP Free
01/08/20 5:09 PM
profile icon
knoxlube Free
01/08/20 4:36 PM
profile icon
knoxlube Free
01/08/20 12:41 PM
profile icon
RodinLP Free
01/08/20 9:51 AM
profile icon
knoxlube Free
01/08/20 8:29 AM
profile icon
davidsson10 Free
01/07/20 4:35 PM
profile icon
RodinLP Free
01/07/20 9:48 AM
profile icon
knoxlube Free
01/06/20 6:37 PM
profile icon
RodinLP Free
01/06/20 5:13 PM
profile icon
knoxlube Free
01/06/20 12:11 PM
profile icon
ADVFN_bioking Terminated
01/06/20 11:05 AM
profile icon
ADVFN_bioking Terminated
01/06/20 10:54 AM
profile icon
eom7 Free
01/06/20 10:17 AM
profile icon
ADVFN_bioking Terminated
01/06/20 9:53 AM
profile icon
ADVFN_bioking Terminated
01/06/20 9:31 AM
profile icon
ADVFN_bioking Terminated
01/06/20 8:31 AM
profile icon
ADVFN_bioking Terminated
01/05/20 7:10 PM
profile icon
eom7 Free
01/03/20 3:51 PM
profile icon
ADVFN_bioking Terminated
01/03/20 2:01 PM
profile icon
kwintz Free
01/03/20 1:45 PM
profile icon
ADVFN_bioking Terminated
01/03/20 1:35 PM
profile icon
ADVFN_bioking Terminated
01/03/20 11:53 AM
profile icon
ADVFN_bioking Terminated
01/03/20 11:37 AM
profile icon
ADVFN_bioking Terminated
01/03/20 10:54 AM
profile icon
RodinLP Free
01/03/20 10:03 AM

LadRx Corp (LADXD) RSS Feed

Followers
205
Posters
563
Posts (Today)
0
Posts (Total)
7747
Created
01/22/05
Type
Free
Moderators
BRUTALLY underpriced Biotech with a laughable market cap of only $10 million trading under their Cash balance of $18.5 million (or Cash untill 2023+)  . CYTR has a very large pipeline with multiple Phase 3 und Phase 2 partnered programs ongoing targeting Rare Diseases and Cancer .Most advanced Drug is Arimoclomol for the treatment of Nieman-Pick Disease for which they expect to submit NDA and MAA in Q2 with potential approval in the US and Europe in Q4 this will trigger a $10 million milestone payment to CYTR . More Big News expected within 6 months like the Phase 2 readout of the Gaucher Disease trial and the Phase 3 interim results of sIBM trial (more infos below)  .This low float stock has everything to be the next 10+ Bagger at current price the stock is more than a PURE GIFT . STRONG BUY and GL


CytRx (CYTR)

Market-Cap: $9,8 M
Cash: $18,5 M ( Cash untill 2023+ )
Price: $0,29

Shares Out: 33,6 M

Burn-rate: only $1.2 M per Quarter
NO Debt



Upcoming Catalysts of the Rare Disease Pipeline :

Niemann-Pick disease Type C (NPC)--Early access program in January -- NDA/MAA filing in Q2 2020 ---There are no approved treatments for NPC in the USA and only one approved product in Europe. Arimoclomol has been granted Orphan Drug Designation (EU and USA), Rare Pediatric Disease Designation (USA), and Fast Track designation (USA) for the treatment of NPC.

Sporadic Inclusion Body Myositis (sIBM) Phase 2/3 interim results in Q1 2020 -- very large market potential --There are no approved treatments for sIBM. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of sIBM. 

Amyotrophic Lateral Sclerosis (ALS) interim results Q1/Q2 2020 --very large market potential --Currently, there are only limited treatment options available. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of ALS.

Gaucher disease typ III--Phase 2 results in Q1 ---Effective treatments are available for the systemic manifestations of the disease – however, no therapies are available for the neurological symptoms.




Presentation December 2019
http://www.cytrx.com/wp-content/uploads/2019/12/CYTR-Corp-Overview-December-2019-Non-Conf.pdf


CytRx Corporation - Biopharmaceutical Company Discusses Near Term Value from Out-License Deals and Growth Drivers
https://stocknewsnow.com/commentary/ANEWSID26062019100002/VIDEO-CytRx-Corporation-(OTCQB-CYTR)


Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
https://finance.yahoo.com/news/orphazyme-arimoclomol-receives-us-fast-060058985.html


Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
https://finance.yahoo.com/news/orphazyme-receives-breakthrough-therapy-designation-060000973.html








LADXD Latest News
  • No Recent News Available for this company!
New Post